KR101488691B1 - 비페닐-2-일카르밤산 1-〔2-（2-클로로-4-｛〔（ｒ）-2-히드록시-2-（8-히드록시-2-옥소-1,2-디히드로퀴놀린-5-일）에틸아미노〕메틸｝-5-메톡시페닐카르바모일）에틸〕피페리딘-4-일 에스테르의 석신산 염 및 이의 폐질환 치료를 위한 용도 - Google Patents

비페닐-2-일카르밤산 1-〔2-（2-클로로-4-｛〔（ｒ）-2-히드록시-2-（8-히드록시-2-옥소-1,2-디히드로퀴놀린-5-일）에틸아미노〕메틸｝-5-메톡시페닐카르바모일）에틸〕피페리딘-4-일 에스테르의 석신산 염 및 이의 폐질환 치료를 위한 용도 Download PDF

Info

Publication number
KR101488691B1
KR101488691B1 KR20087022160A KR20087022160A KR101488691B1 KR 101488691 B1 KR101488691 B1 KR 101488691B1 KR 20087022160 A KR20087022160 A KR 20087022160A KR 20087022160 A KR20087022160 A KR 20087022160A KR 101488691 B1 KR101488691 B1 KR 101488691B1
Authority
KR
South Korea
Prior art keywords
ethyl
hydroxy
salt
delete delete
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR20087022160A
Other languages
English (en)
Korean (ko)
Other versions
KR20080114723A (ko
Inventor
레시마 추다사마
앤드류 케네디
린다 제인 킨돈
프랭크 패트릭 말렛
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101488691(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20080114723A publication Critical patent/KR20080114723A/ko
Application granted granted Critical
Publication of KR101488691B1 publication Critical patent/KR101488691B1/ko
Assigned to 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 reassignment 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 권리의 전부이전등록 Assignors: 글락소 그룹 리미티드
Assigned to 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 reassignment 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 권리의 전부이전등록 Assignors: 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
KR20087022160A 2006-02-10 2007-02-08 비페닐-2-일카르밤산 1-〔2-（2-클로로-4-｛〔（ｒ）-2-히드록시-2-（8-히드록시-2-옥소-1,2-디히드로퀴놀린-5-일）에틸아미노〕메틸｝-5-메톡시페닐카르바모일）에틸〕피페리딘-4-일 에스테르의 석신산 염 및 이의 폐질환 치료를 위한 용도 Expired - Fee Related KR101488691B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0602778.3 2006-02-10
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound
PCT/EP2007/051196 WO2007090859A1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [ (r)-2-hydroxy-2- (8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) eth ylaminoimethyl] } -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders

Publications (2)

Publication Number Publication Date
KR20080114723A KR20080114723A (ko) 2008-12-31
KR101488691B1 true KR101488691B1 (ko) 2015-02-02

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20087022160A Expired - Fee Related KR101488691B1 (ko) 2006-02-10 2007-02-08 비페닐-2-일카르밤산 1-〔2-（2-클로로-4-｛〔（ｒ）-2-히드록시-2-（8-히드록시-2-옥소-1,2-디히드로퀴놀린-5-일）에틸아미노〕메틸｝-5-메톡시페닐카르바모일）에틸〕피페리딘-4-일 에스테르의 석신산 염 및 이의 폐질환 치료를 위한 용도

Country Status (33)

Country Link
US (1) US7960551B2 (https=)
EP (1) EP1981872B1 (https=)
JP (1) JP5616021B2 (https=)
KR (1) KR101488691B1 (https=)
CN (1) CN101379057B (https=)
AR (2) AR059409A1 (https=)
AU (1) AU2007213767B2 (https=)
BR (1) BRPI0707559B8 (https=)
CA (1) CA2641769C (https=)
CR (1) CR10227A (https=)
CY (1) CY1119238T1 (https=)
DK (1) DK1981872T3 (https=)
EA (1) EA016580B1 (https=)
ES (1) ES2640226T3 (https=)
GB (1) GB0602778D0 (https=)
HR (1) HRP20171304T1 (https=)
HU (1) HUE034315T2 (https=)
IL (1) IL193103A (https=)
JO (1) JO3389B1 (https=)
LT (1) LT1981872T (https=)
MA (1) MA30273B1 (https=)
MY (1) MY153656A (https=)
NO (1) NO341343B1 (https=)
NZ (1) NZ570242A (https=)
PE (2) PE20110120A1 (https=)
PL (1) PL1981872T3 (https=)
PT (1) PT1981872T (https=)
SG (1) SG169404A1 (https=)
SI (1) SI1981872T1 (https=)
TW (1) TWI401251B (https=)
UA (1) UA100364C2 (https=)
WO (1) WO2007090859A1 (https=)
ZA (1) ZA200806782B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175023A1 (en) 2009-04-14 2011-11-28 Glaxo Group Ltd Process for the preparation of a biphenyl-2-ylcarbamic acid ester
SG175330A1 (en) 2009-04-23 2011-11-28 Theravance Inc DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
WO2013017494A1 (en) * 2011-08-02 2013-02-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition of oxidised avidin suitable for inhalation
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (es) * 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074246A2 (en) * 2003-02-14 2004-09-02 Theravance Inc. Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
CZ236894A3 (en) 1992-03-31 1995-09-13 Glaxo Group Ltd Substituted phenylcarbonates and phenylureas, their use for the preparation of pharmaceutical preparations, pharmaceuticals containing thereof and process for preparing such compounds
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
SG80041A1 (en) 1998-06-08 2001-04-17 Advanced Medicine Inc Muscarinic receptor antagonists
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
AU783095B2 (en) 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
NZ522882A (en) 2000-06-05 2004-07-30 Altana Pharma Bv Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
EP1497289B1 (de) 2002-04-12 2005-08-24 Boehringer Ingelheim Pharma GmbH & Co.KG Arzneimittel enthaltend betamimetika und ein neues anticholinergikum
EP1507754A1 (en) * 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
DE602004021921D1 (de) * 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
US7345060B2 (en) * 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
US7569586B2 (en) * 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074246A2 (en) * 2003-02-14 2004-09-02 Theravance Inc. Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
JP2009526018A (ja) 2009-07-16
TW200800948A (en) 2008-01-01
MY153656A (en) 2015-03-13
WO2007090859A1 (en) 2007-08-16
SI1981872T1 (sl) 2017-10-30
SG169404A1 (en) 2011-03-30
US20070281971A1 (en) 2007-12-06
EP1981872B1 (en) 2017-06-21
CR10227A (es) 2008-10-29
EA016580B1 (ru) 2012-06-29
HUE034315T2 (en) 2018-02-28
PT1981872T (pt) 2017-09-13
EA200801691A1 (ru) 2009-02-27
NZ570242A (en) 2011-09-30
AU2007213767A1 (en) 2007-08-16
BRPI0707559A2 (pt) 2011-05-10
PE20071249A1 (es) 2008-01-16
ZA200806782B (en) 2009-10-28
NO20083425L (no) 2008-09-09
IL193103A (en) 2013-06-27
TWI401251B (zh) 2013-07-11
AR059409A1 (es) 2008-04-09
HRP20171304T1 (hr) 2017-10-20
GB0602778D0 (en) 2006-03-22
DK1981872T3 (en) 2017-09-11
JP5616021B2 (ja) 2014-10-29
JO3389B1 (ar) 2019-03-13
BRPI0707559B8 (pt) 2021-05-25
LT1981872T (lt) 2017-09-11
UA100364C2 (xx) 2012-12-25
PL1981872T3 (pl) 2017-11-30
CN101379057B (zh) 2013-02-13
PE20110120A1 (es) 2011-03-08
EP1981872A1 (en) 2008-10-22
IL193103A0 (en) 2009-02-11
KR20080114723A (ko) 2008-12-31
BRPI0707559A8 (pt) 2019-01-29
BRPI0707559B1 (pt) 2021-01-12
CY1119238T1 (el) 2018-02-14
NO341343B1 (no) 2017-10-16
CA2641769C (en) 2014-02-04
US7960551B2 (en) 2011-06-14
CA2641769A1 (en) 2007-08-16
CN101379057A (zh) 2009-03-04
AR104288A2 (es) 2017-07-12
ES2640226T3 (es) 2017-11-02
MA30273B1 (fr) 2009-03-02
AU2007213767B2 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
KR101488691B1 (ko) 비페닐-2-일카르밤산 1-〔2-（2-클로로-4-｛〔（ｒ）-2-히드록시-2-（8-히드록시-2-옥소-1,2-디히드로퀴놀린-5-일）에틸아미노〕메틸｝-5-메톡시페닐카르바모일）에틸〕피페리딘-4-일 에스테르의 석신산 염 및 이의 폐질환 치료를 위한 용도
CN103140485B (zh) 二酰胺化合物的结晶草酸盐
TW201522341A (zh) 化合物
WO2010126953A1 (en) Corticosteroid linked beta-agonist compounds for use in therapy
JP6134377B2 (ja) β２アドレナリン受容体作動薬としての、５−（２−｛［６−（２，２−ジフルオロ−２−フェニルエトキシ）ヘキシル］アミノ｝−１−（Ｒ）−ヒドロキシエチル）−８−ヒドロキシキノリン−２（１Ｈ）−オンヘミナパジシル酸塩の新規の多型結晶形態
KR20200030107A (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
KR20080024532A (ko) 신규한 티오트로퓸 염의 제조방법, 신규한 티오트로퓸 염및 이의 약제학적 조성물
HK1119703A (en) Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2-hydroxy-2-(8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) ethylaminoimethyl]}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester and its use for the treatment of pulmonary disorders
HK1119703B (en) Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2-hydroxy-2-(8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) ethylaminoimethyl]}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester and its use for the treatment of pulmonary disorders
MX2008010205A (es) Sal de acido succinico de 1-[2-(2-cloro-4-[{[r]-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester de acido bifenil-2-ilcarbamico y su uso en el tratamiento de trastornos pulmonar
JP7627683B2 (ja) Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態
JP2011519874A (ja) ８−ヒドロキシ−５−［（１ｒ）−１−ヒドロキシ−２−［［（１ｒ）−２−（４−メトキシフェニル）−１−メチルエチル］アミノ］エチル］−２（１ｈ）−キノリノン一塩酸塩の結晶形

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240128

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240128